目的 系统评价热疗联合静脉化疗治疗卵巢癌的有效性和安全性.方法 计算机检索PubMed、Cochrane library、EMbase、中国学术期刊全文数据库、中国生物医学文献数据库等,搜索年限从建库到2017年6月22日.纳入热疗联合静脉化疗治疗卵巢癌效果与安全性方面的随机对照研究.使用Cochrane手册5.1.0版的质量评价标准对纳入研究进行质量评价,使用RevMan 5.1.0版软件进行数据分析.结果 最终纳入20项研究,共1275例患者.Meta分析结果显示:与对照组比较,治疗组有效率[RR=1.58,95％CI:1.42～1.77,P＜0.00 001],腹水有效率[RR=1.63,95％CI:1.32～2.02,P＜0.00 001],CA125有效率[RR=1.33,95％CI:1.14～1.55,P=0.0003],生活质量改善率[RR=1.60,95％CI:1.24～2.06,P=0.0003]均提高.热疗联合静脉化疗并不增加骨髓抑制、恶心呕吐、肝肾损害等的发生率(P＞0.05).结论 热疗联合静脉化疗可提高卵巢癌的疗效,改善生活质量,且不增加毒副作用.%Objective To evaluate the effectiveness and safety of hyperthermia combined with intravenous chemotherapy for ovarian cancer.Methods The databases of PubMed,Cochrane library,EMbase,China national knowledge internet,the Chinese biomedical literature database were searched from building to June 22,2017.Randomized controlled studies on the efficacy and safety of hyperthermia combined with intravenous chemotherapy in the treatment of ovarian cancer were included,the quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0,and the Review Manager 5.1.0 software was used for data analysis.Results Twenty studies including 1275 cases of ovarian cancer were included.The results of the Meta-analvsis exhibited that compared with intravenous chemotherapy alone,hyperthermia combined with intravenous chemotherapy could increase effective rate [RR =1.58,95％CI:1.42-1.77,P ＜ 0.00 001],effective rate of ascites[RR =1.63,95％CI:1.32-2.02,P ＜ 0.00 001],effective rate of CA125 [RR =1.33,95％CI:.1.14-1.55,P =0.0003],the improvement rate of life quality [RR =1.60,95％CI:1.24-2.06,P =0.0003].Meanwhile,hyperthermia combined with intravenous chemotherapy did not significantly increase the incidence of myelosuppression,nausea and vomiting and liver and kidney dysfunction (P ＞ 0.05).Conclusion Hyperthermia combined with intravenous chemotherapy may be more effective for ovarian cancer,improve life quality whereas adverse reactions are similar.
展开▼
